APOGEE THERAPEUTICS INC(NASDAQ:APGE) stock News

APGE Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Chartmill - Mentions: PBM CDZI NCI RGP ...

What's going on in today's after hours session

14 days ago - By: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

14 days ago - By: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

15 days ago - By: The Motley Fool

Why Apogee Therapeutics Stock Triumphed on Thursday

15 days ago - By: Stocktwits - Mentions: SPY QQQ DIA DAL ...

Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today

15 days ago - By: Investor's Business Daily - Mentions: REGN SNY

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

15 days ago - By: Benzinga - Mentions: IVA HELE PLUG AZZ ...

Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

15 days ago - By: Benzinga - Mentions: TELO YYAI IHT DGNX ...

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

15 days ago - By: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

15 days ago - By: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

16 days ago - By: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

16 days ago - By: Apogee Therapeutics

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

a month ago - By: Apogee Therapeutics

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

a month ago - By: Apogee Therapeutics

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

2 months ago - By: Apogee Therapeutics

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

2 months ago - By: Apogee Therapeutics

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

2 months ago - By: Apogee Therapeutics

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

2 months ago - By: Apogee Therapeutics

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

3 months ago - By: Yahoo Finance

Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug

3 months ago - By: Yahoo Finance - Mentions: GS EXAS

BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating

3 months ago - By: Yahoo Finance - Mentions: MTSR JPM

Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association

3 months ago - By: Yahoo Finance - Mentions: JPM

Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)

4 months ago - By: Yahoo Finance - Mentions: PEP

Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors

4 months ago - By: Yahoo Finance - Mentions: PEP RGC GFS

GlobalFoundries Stock Pops on AI Chip Designer Acquisition

4 months ago - By: Investor's Business Daily - Mentions: LLY SNY REGN

APOGEE THERAPEUTICS INC (APGE) Stock News

APGE Latest News, Press Relases and Analysis

What's going on in today's after hours session

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

Why Apogee Therapeutics Stock Triumphed on Thursday

Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug

BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating

Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association

Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)

Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors

GlobalFoundries Stock Pops on AI Chip Designer Acquisition

Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot